NGFN-PLUS
Mutanom
Coordinator: | PD Dr. Bodo M.H. Lange | |
Institution: | Max-Planck Institut für molekulare Genetik | |
Homepage: | www.molgen.mpg.de |
Koordinator: Prof. Dr. Hans Lehrach
Institut: Max-Planck Institut für molekulare Genetik
Homepage: www.molgen.mpg.de
Funded through the NGFN Plus Research initiative, the IG Mutanom characterises the functional consequences of somatic mutations and develops models that predict the outcome of such genetic alterations on a molecular pathway level, cellular and organism level. From very early on in this project our results are translated into the clinical and Public Health sector with the goal to define new diagnostic and therapeutic strategies. First, the effort concentrates on characterising „driver“ mutations (i.e. mutations that occur in cancer due to selective pressure) that already have been selected from databases and from the scientific literature, which will be characterised in close collaboration among the different subprojects. The consortium has complementary expertises in the fields of proteomics (MPIMG, DKFZ, MDC) functional genomics (MPI-MG, DKFZ) and modelling (MPIMG). Clinical partners and companies (e.g. Cellzome) are part of the project and carry out mass spectrometry analysis, expression profiling, provide tissue samples or clones. Academic experts (SOCMED) ensure from the early beginning of the project that the translational aspects of the project is fully exploited.
Latest results can be found in detail in the descriptions of the subprojects
Institut: Max-Planck Institut für molekulare Genetik
Homepage: www.molgen.mpg.de
Funded through the NGFN Plus Research initiative, the IG Mutanom characterises the functional consequences of somatic mutations and develops models that predict the outcome of such genetic alterations on a molecular pathway level, cellular and organism level. From very early on in this project our results are translated into the clinical and Public Health sector with the goal to define new diagnostic and therapeutic strategies. First, the effort concentrates on characterising „driver“ mutations (i.e. mutations that occur in cancer due to selective pressure) that already have been selected from databases and from the scientific literature, which will be characterised in close collaboration among the different subprojects. The consortium has complementary expertises in the fields of proteomics (MPIMG, DKFZ, MDC) functional genomics (MPI-MG, DKFZ) and modelling (MPIMG). Clinical partners and companies (e.g. Cellzome) are part of the project and carry out mass spectrometry analysis, expression profiling, provide tissue samples or clones. Academic experts (SOCMED) ensure from the early beginning of the project that the translational aspects of the project is fully exploited.
Latest results can be found in detail in the descriptions of the subprojects
- TP1 Project coordination
- TP2 Translational Health Research
- TP3 Mutational analysis
- TP4 Recombinant cancer cell libraries & drug target recovery
- TP5 Quantification of cancer pathways
- TP6 Protein interaction networks
- TP7 Cellular signalling networks
- TP8 Mouse disease models
- TP9 Protein complex composition and function in disease
- TP10 Data integration and modelling
- TP11 Quantitative Proteomics
- Publications
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS